Page 47 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 11 ฉบับที่ 3

256 «“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë 11 ©∫—∫∑’Ë 3°—𬓬π-∏—𫓧¡ 2556

“√≈–≈“¬μ—«Õ¬à“ß·≈– “√≈–≈“¬¡“μ√∞“π ª√‘¡“≥ “√§«∫§ÿ¡∫«° (positive control) §◊Õ rifampi-
25.0 ‰¡‚§√≈‘μ√ ‡μ√’¬¡πÈ”¬“·¬°‚¥¬„™â√–∫∫ gra- cin ‡∑à“°—∫ 0.047 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√, kanamy-

dient ¢Õß “√≈–≈“¬πÈ”·≈–‡¡∑“πÕ≈ „πÕ—μ√“ à«π cin ‡∑à“°—∫ 1.25 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√, isoniazid
95:5 ®π∂÷ß 0:100 —߇°μæ’§∑’ˇ°‘¥¢÷Èπ‚¥¬„™â photo- ‡∑à“°—∫ 0.250 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√; ƒ∑∏‘Ïμâ“π‡™◊ÈÕ‡√‘¡
diode array detector ∑’˧«“¡¬“«§≈◊Ëπ 279 ·≈– (Anti-HSV-1) (Herpes simplex virus type 1)

324 π“‚π‡¡μ√ ¥â«¬«‘∏’ SRB (Sulforhodamine B) Assay ‚¥¬
3. °“√æ‘ Ÿ®πå Ÿμ√‚§√ß √â“ß∑“߇§¡’¢Õß “√ §«“¡‡¢â¡¢âπ Ÿß ÿ¥¢Õßμ—«Õ¬à“ß §◊Õ 50 ‰¡‚§√°√—¡/
∫√‘ ÿ∑∏‘Ï∑’Ë·¬°‰¥â ¡‘≈≈‘≈‘μ√ ·≈–§à“§«“¡‡¢â¡¢âπ∑’ˬ—∫¬—È߇™◊ÈÕ‰¥â√âÕ¬≈– 50

π” “√∫√‘ ÿ∑∏‘Ï 1-3 ∑’Ë·¬°‰¥â¡“æ‘ Ÿ®πå Ÿμ√ (IC ) ¢Õß positive control §◊Õ acyclovir ‡∑à“°—∫
50
‚§√ß √â“ß∑“߇§¡’‚¥¬„™â‡∑§π‘§ ‡ª°‚∑√ ‚§ªï ‚¥¬ 2.09 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√; ƒ∑∏‘Ïμâ“π¡“≈“‡√’¬ (Anti-
àßμ√«® Õ∫∑’ËÀπ૬ªØ‘∫—μ‘°“√«‘®—¬°≈“߉∫‚Õ‡∑§ malarial) μàÕ Plasmodium falciparum ¥â«¬‡∑§π‘§

»Ÿπ¬åæ—π∏ÿ«‘»«°√√¡·≈–‡∑§‚π‚≈¬’™’«¿“æ·Ààß™“μ‘ Microculture Radioisotope ‚¥¬§«“¡‡¢â¡¢âπ
(BIOTEC) ‚¥¬„™â‡§√◊ËÕß NMR (Bruker-AV500), Ÿß ÿ¥¢Õßμ—«Õ¬à“ß §◊Õ 10 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ ·≈–
Mass spectrometer (MS 1200 L Quadrupole IC50 ¢Õß positive control §◊Õ dihydro-

MS/MS (Varian) artemisinin ‡∑à“°—∫ 4.1 π“‚π‚¡≈“√å; ƒ∑∏‘Ïμâ“π°“√
4. °“√∑¥ Õ∫ƒ∑∏‘Ï∑“ß™’«¿“æ Õ—°‡ ∫ (Anti-inflammatory) ¥â«¬°“√¬—∫¬—È߇Õπ‰´¡å
“√ °—¥À¬“∫πÈ”®“° à«π‡Àπ◊Õ¥‘π·¡ß≈—°§“ COX-1, COX-2 ¥â«¬«‘∏’ Radioimmunoassay
·≈– “√∫√‘ ÿ∑∏‘Ï 1-3 ∑’Ë·¬°‰¥â∂Ÿ° à߉ª∑¥ Õ∫ƒ∑∏‘Ï (RIA) ‚¥¬§«“¡‡¢â¡¢âπ Ÿß ÿ¥¢Õßμ—«Õ¬à“ß §◊Õ 10

∑“ß™’«¿“æ∑’Ë ∂“∫—π«‘®—¬«‘∑¬“»“ μ√å “∏“√≥ ÿ¢ ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ ·≈– IC ¢Õß positive con-
50
°√¡«‘∑¬“»“ μ√å°“√·æ∑¬å °√–∑√«ß “∏“√≥ ÿ¢ ∑’Ë trol μàÕ COX-1, COX-2 §◊Õ aspirin ‡∑à“°—∫ 5, 10

ΩÉ“¬‰«√— √–∫∫∑“߇¥‘πÀ“¬„® ‚¥¬∑¥ Õ∫°—∫‡™◊ÈÕ ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ μ“¡≈”¥—∫; §«“¡‡ªìπæ‘…μàÕ
‰«√— ‰¢âÀ«—¥„À≠à (Flu A/H3) ¥â«¬«‘∏’ Plaque Re- ‡´≈≈å¡–‡√Áß (Cytotoxicity) μàÕ KB (oral human
duction Assay ·≈–∑’ËΩÉ“¬ªØ‘∫—μ‘°“√μâ“π‡™◊ÈÕ epidermal carcinoma) ¥â«¬«‘∏’ SRB Assay,
Õ—πμ√“¬ Ÿß·≈–¿Ÿ¡‘§ÿâ¡°—π«‘∑¬“ ‚¥¬∑¥ Õ∫°“√ MCF-7 (breast cancer) ¥â«¬«‘∏’ SRB Assay, NCI-

¬—∫¬—È߇™◊ÈÕ HIV-1 ¥â«¬«‘∏’ Immunofluorescence H187 (human, small cell lung cancer) ¥â«¬«‘∏’
Assay πÕ°®“°π’È “√∫√‘ ÿ∑∏‘Ï 2-3 ‰¥â∂Ÿ° à߉ª MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-

∑¥ Õ∫ƒ∑∏‘Ï∑“ß™’«¿“æÕ◊Ëπ Ê ∑’Ë BIOTEC ‰¥â·°à diphenyltetrazolium bromide) Assay ‚¥¬
ƒ∑∏‘Ϭ—∫¬—È߇™◊ÈÕ«—≥‚√§ (Anti-Mycobacterium tu- §«“¡‡¢â¡¢âπ Ÿß ÿ¥¢Õßμ—«Õ¬à“ß §◊Õ 20 ‰¡‚§√°√—¡/
berculosis H37Ra strain) ¥â«¬«‘∏’ Resazurin ¡‘≈≈‘≈‘μ√ ·≈– IC ¢Õß positive control μàÕ KB,
50
Microplate Assay (REMA) ‚¥¬§«“¡‡¢â¡¢âπ MCF-7, NCI-H187 §◊Õ doxorubicin ‡∑à“°—∫ 0.095,

Ÿß ÿ¥¢Õßμ—«Õ¬à“ß §◊Õ 200 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ 0.243, 0.026 ‰¡‚§√°√—¡/¡‘≈≈‘≈‘μ√ μ“¡≈”¥—∫ ·≈–
·≈–§à“§«“¡‡¢â¡¢âπμË” ÿ¥∑’ˬ—∫¬—È߇™◊ÈÕ (MIC) ¢Õß ƒ∑∏‘Ïμâ“π‡™◊ÈÕ√“ (Anti-fungal against Candida